Der Einfluss multipler Anti-VEGF-Injektionen auf den intraokularen Druck

Lamprakis, Ioannis; Todorova, Margarita G.; Grüb, Matthias; Schlote, Torsten

doi:10.1055/s-0043-118851

Cited by 4 publications

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Der Autor, der einen glaukomatologischen Schwerpunkt hat, kennt aber aus eigener Erfahrung nicht wenige Patienten, die nach IVOM und bei einseitiger IVOM nur am IVOM-Auge trotz bisheriger Normotonie Probleme mit dem Augendruck entwickelt haben. Obwohl es einzelne Studien gibt, nach denen eine IVOM, abgesehen von Patienten mit präexistentem Glaukom, "glaukomatologisch unbedenklich" ist [3], sollte der Augendruck bei der IVOM-Indikationsstellung mit in die Überlegungen einbezogen werden. Druckspitzen abgefangen werden.…”

unclassified

Sicherheit, Effektivität und protektive Wirkung einer Parazentese bei intravitrealen Injektionen. Zum Beitrag von M. J. Koss et al. (Leserbrief)

Rohrbach

2020

Klin Monbl Augenheilkd

View full text Add to dashboard Cite

unclassified

Sicherheit, Effektivität und protektive Wirkung einer Parazentese bei intravitrealen Injektionen. Zum Beitrag von M. J. Koss et al. (Leserbrief)

Rohrbach

2020

Klin Monbl Augenheilkd

View full text Add to dashboard Cite

Acute and subacute macular and peripapillary angiographic changes in choroidal and retinal blood flow post-intravitreal injections

Arumuganathan

Wiest

Toro

et al. 2021

Sci Rep

View full text Add to dashboard Cite

Whether post injectional acute intraocular pressure (IOP) increase is associated with decreased peripapillary and macular perfusion is still under debate. Here, we investigated early changes in the choroidal and retinal blood flow using OCTA imaging in a cohort of patients undergoing anti-VEGF intravitreal injections (IVI) for macular edema following retinal vein occlusion and diabetic retinopathy. In this prospective single-center, observational study, the pre- and post-IVI changes in retinal perfusion were examined via assessment of vessel length density (VLD) and vessel density (VD) in deep and superficial capillary segmentations (DCP and SCP), foveal avascular zone (FAZ) in SCP, as well as flow signal deficits in the choriocapillaris segmentation. Mean IOP significantly changed over the study course (p = 0.000; ANOVA). Measurements at 5 min post-IVI (33.48 ± 10.84 mmHg) differed significantly from baseline (17.26 ± 2.41 mmHg, p = 0.000), while measurements from one day, one week, and one-month post-IVI did not (p = 0.907, p = 1.000 and p = 1.000 respectively). In comparison to baseline, no changes in OCTA parameters, including FAZ, VD, VLD, and FV, were detected 5 min post-IVI. No significant alterations in OCTA parameters were observed during study course. Increased IOP spikes were detected post-IVI; however, no potential permanent ischemic retinal damage was suspected.

show abstract

Comparison of intravitreal ranibizumab monotherapy vs. ranibizumab combined with dexamethasone implant for macular edema secondary to retinal vein occlusion

Liang

Shen

et al. 2022

Front. Med.

View full text Add to dashboard Cite

PurposeTo compare the efficacy and the injection number of intravitreal ranibizumab (IVR) monotherapy vs. intravitreal ranibizumab plus dexamethasone (IVR + DEX) implants for macular edema (ME) secondary to retinal vein occlusion (RVO).MethodsThis prospective, control trial comprised 96 eyes of 96 patients with ME due to non-ischemic RVO divided into two groups. The IVR monotherapy group consisted of 61 patients (29 with CRVO and 32 with BRVO) treated with ranibizumab with three consecutive loading doses at a monthly + pro re nata (three + PRN) regimen. The IVR + DEX implant group consisted of 35 patients (19 with CRVO and 16 with BRVO) treated with intravitreal ranibizumab plus DEX implant. All eyes underwent best-corrected visual acuity (BCVA, log MAR), central foveal thickness (CFT), and intraocular pressure (IOP). In case of recurrence, each group received initial medication.ResultsAt the 12-month visit, the mean log MAR BCVA that was improved from baseline was 0.23 with the IVR group and 0.30 with the IVR + DEX group. CFT decreased on average by 420 ± 292 μm with the IVR group and 393 ± 259 μm with the IVR + DEX implant group. No significant differences were detected in BCVA improvement and CFT reduction between the two groups (p > 0.05). The mean number of injections was 5.4 in the IVR group and 3.9 in the IVR + DEX implant group (p < 0.001). The mean reinjection interval for patients with the IVR + DEX implant was 131.2 ± 8.9 days (range: 98–150). The incidence of high IOP and cataract progression were significantly higher in the IVR + DEX implant group than in the IVR group (both p < 0.001).ConclusionIn RVO-ME, the IVR + DEX implant did not have synergistic efficacy, providing further improvement in BCVA and a reduction in CFT. However, the IVR + DEX implant still had an advantage in reducing the number of injections and prolonging the time between injections.

show abstract

Der Einfluss multipler Anti-VEGF-Injektionen auf den intraokularen Druck

Abstract: Multiple anti-VEGF injections are not associated with an increased risk of sustained IOP-elevation. On the other hand, individual risk factors exist and predispose to IOP-elevation (e.g., pre-existing glaucoma).

Cited by 4 publications

References 23 publications

Sicherheit, Effektivität und protektive Wirkung einer Parazentese bei intravitrealen Injektionen. Zum Beitrag von M. J. Koss et al. (Leserbrief)

Sicherheit, Effektivität und protektive Wirkung einer Parazentese bei intravitrealen Injektionen. Zum Beitrag von M. J. Koss et al. (Leserbrief)

Acute and subacute macular and peripapillary angiographic changes in choroidal and retinal blood flow post-intravitreal injections

Comparison of intravitreal ranibizumab monotherapy vs. ranibizumab combined with dexamethasone implant for macular edema secondary to retinal vein occlusion

Contact Info

Product

Resources

About